On Third Of Children Medications Are Only Tested On Adults Leading To Improper Use

Did you know that about 30% of drugs prescribed children medications have never even been tested on children?  Or, did you know that up to 95% of drugs given to babies in intensive care – have never been tested on them either?

According to a new report, these statistics are true, and children are being prescribed unlicensed medicines that could be causing harm. This begs the question, are prescription children medications safe?

And, the new government study is demanding an urgent investigation into the “unacceptable” fact that almost a third of drugs given to sick children are officially approved for only adult use.

It warns of “a high number of drug errors” in which children may be wrongly prescribed too much of a medicine because the doses are meant for adults.

In the past, pharmaceutical companies have not had an obligation to test medicines on children. The law changed in 2007 and new drugs coming to market must now be tested on children before they can be used on them.

But, that still leaves the older drugs untested that were approved before 2007, which includes common antibiotics, painkillers, asthma inhalers and cancer medicines.

According to the Daily Mail, the UK Department of Health commissioned the study and the resulting report was written by “leading child health experts,” This was called the “Children and Young People’s Health Outcomes Forum”.

The lack of formal testing is alarming to the Health Outcomes forum because no one knows how many children may have had problems that were never reported or properly acknowledged. This could be placing an unknown burden on the UK health system. The Medicines and Healthcare products Regulatory Agency would be the appropriate agency to conduct such an in-depth investigation.

Lack Of Guidelines For Children Medicines

The reasoning is that the Department of Health does not give guidelines for prescribing unlicensed drugs to children and therefore the potential for drug errors is much higher.

The report, from the Children and Young People’s Health Outcomes Forum, says: “New medicines account for a relatively small percentage of those used by children, and those introduced before [the 2007] legislation largely remain unregulated and, critically, therefore possibly untested formally in children.

“This contributes to the high number of drug errors and leads to wider implications – including the fact that the National Institute for Health and Clinical Excellence will not give advice on unlicensed medicines and this limits the guidance that they can offer on care for children.”

It goes on to caution: “The Forum believes that the situation with regard to the absence of licensing for the majority of children and young people’s medicines in this country is unacceptable.”

One roadblock to testing new drugs on children is the ethical concern about testing drugs on children. Regulators have made it difficult for drug companies to get approval for such testing. Lack of any regulatory requirement is another issue. Once a drug is approved for adults, there is no requirement that drug companies test the drugs on children. This helps the drug companies finances but may indicate some lobbying or influence peddling with government.

Some believe that a lack of formal testing on children is not as much of a problem as the investigators say it is. And that it would be more of a hassle and financial burden in order to test medications that have been used on the market for decades.

, , , , , ,

No comments yet.

Leave a Reply

  • This field is for validation purposes and should be left unchanged.
Latest Drug Injury News

Paxil Possibly Linked To Breast Cancer Risk

Cancer researchers from the City of Hope National Medical Center announced a possible link between Paxil and breast cancer. Research focused on Paxil’s estrogen effect Researchers found that Paxil has a weak estrogen effect that could increase women’s breast cancer risks. According to lead author and chairman of City of Hope’s Department of Cancer and […]

Big Pharma under Fire for Kickbacks to Docs

Trust and honesty are the cornerstones to a doctor-patient relationship. With so many doctors receiving financial incentives to use certain medications or medical devices, patients need to know if money drives the decision making process. Doctors are required to disclose potential financial conflicts to each other at conferences, but there currently is no law forcing […]

Dietary Supplements Damage Liver

A recent study revealed a significant increase in liver damage related to dietary supplements. The study, conducted by a national network of liver specialists, found a 13% increase in serious liver damage over a 10 year span. Some of these patients required liver transplants and some have even died due to liver failure. Authors of […]

FDA Advisory Committee Supports Approval of Gilead’s HIV Reducing Drug

The pharmaceutical industry may be on the verge of one of the greatest breakthrough’s that this generation has ever seen.

U.S. Health Regulators Issue New Restrictions For Gilenya, Novartis AG’s’ Multiple Sclerosis Pill

In December 2011, the FDA issued a Drug Safety Communication concerning a patient with multiple sclerosis (MS) who died within 24 hours of taking the first dose of Gilenya (fingolimod).

Latest Medical Device Injury News

Report Raises Concerns Over Heart Defibrillator Leads

The Food and Drug Administration (FDA) has just announced that they received a report that a St. Jude Durata cardiac defibrillator lead conductor became externalized; meaning the wire carrying electricity from the heart defibrillator to the heart was exposed through its insulation, a potentially dangerous and life-threatening defect.

HeartSine Class 1 Defibrillator Recall

HeartSine sent out a letter to customers in September, warning that the defibrillators may intermittently turn on and off, eventually depleting the battery.

FDA Medical Device Approval Based On Little Evidence

More than half of the high-risk cardiovascular devices approved in the past decade had no supporting active control data.

St. Jude Medical Gets FDA Warning

St. Jude Medical Inc. said it received a FDA warning about manufacturing and quality-control problems at its Sylmar, California, plant.

Hospira Still Facing Manufacturing And Regulatory Issues

Hospira has sent out 11 device notifications so far in 2013, including recall and device corrections. The company also said it sent notices to customers about some of its infusion pumps that had to either be recalled, fixed or adjusted.